Aerovate Therapeutics, Inc. (AVTE) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Waltham, MA, United States. The current CEO is Timothy P. Noyes.
AVTE has IPO date of 2021-06-30, 4 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $77.68M.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
